Whittier Trust Co. Buys 1,672 Shares of Amgen Inc. $AMGN

Whittier Trust Co. lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.0% during the third quarter, HoldingsChannel.com reports. The firm owned 43,580 shares of the medical research company’s stock after purchasing an additional 1,672 shares during the period. Whittier Trust Co.’s holdings in Amgen were worth $18,080,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in AMGN. State Street Corp lifted its stake in shares of Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares during the period. Bank of America Corp DE purchased a new stake in Amgen during the second quarter worth about $1,831,903,000. Wellington Management Group LLP grew its position in Amgen by 1,102.7% during the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after buying an additional 2,514,254 shares during the period. BlackRock Inc. grew its position in Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Amgen by 702.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock worth $647,126,000 after buying an additional 1,344,010 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research reports. Robert W. Baird lifted their price target on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Citigroup boosted their price target on Amgen from $405.00 to $465.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 4th. Canaccord Genuity Group upped their price target on Amgen from $384.00 to $440.00 and gave the stock a “hold” rating in a report on Wednesday, November 4th. Truist Financial upped their price target on Amgen from $380.00 to $398.00 and gave the stock a “hold” rating in a report on Wednesday, November 4th. Finally, Barclays raised their price objective on Amgen from $400.00 to $430.00 and gave the company an “equal weight” rating in a research note on Monday, November 16th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $428.62.

View Our Latest Report on AMGN

Amgen Price Performance

Amgen stock opened at $435.52 on Friday. Amgen Inc. has a 52 week low of $312.39 and a 52 week high of $483.99. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60. The firm’s 50-day simple moving average is $430.44 and its 200 day simple moving average is $383.81. The firm has a market capitalization of $235.58 billion, a PE ratio of 25.26, a P/E/G ratio of 3.22 and a beta of 0.43.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. During the same period in the prior year, the company earned $5.64 EPS. The firm’s revenue was up 8.5% on a year-over-year basis. On average, equities research analysts predict that Amgen Inc. will post 23.41 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is 58.47%.

About Amgen

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Recommended Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.